Evidence map›Paper›PMID 39923846›Full record

ArticleCellular and molecular gastroenterology and hepatology2025

Congestion Enriches Intra-hepatic Macrophages Through Reverse Zonation of CXCL9 in Liver Sinusoidal Endothelial Cells.

Siyuan Ma, Nawras W Habash, Mrunal K Dehankar, Nidhi Jalan-Sakrikar, Shawna A Cooper, Abid A Anwar, Sofia Jerez, Papawee Sutthirat, Jinhang Gao, Tamir Diamond and 10 more

Abstract read
In one paragraph

Article in Cellular and molecular gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Fontan-Associated Liver Disease.Seminars in liver disease · 2025
    Review
  7. Liver Traffic Jam: How Sinusoidal Congestion Rewires Macrophage Distribution via CXCL9.Cellular and molecular gastroenterology and hepatology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Siyuan MaDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
Nawras W HabashDivision of Gastroenterology and Hepatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Mrunal K DehankarDepartment of Bioinformatics, Mayo Clinic, Rochester, Minnesota.
Nidhi Jalan-SakrikarDivision of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Shawna A CooperDivision of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota; Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, Minnesota.
Abid A AnwarDivision of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Sofia JerezDivision of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Papawee SutthiratDivision of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Jinhang GaoLaboratory of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, China.
Tamir DiamondDivision of Gastroenterology and Hepatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Department of Pediatrics, University of Pennsylvania, Philadelphia, Pennsylvania.
Jing JiaoDivision of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Caixin QiuDepartment of Radiology, Mayo Clinic, Rochester, Minnesota.
Jingchun YangDivision of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Sumera I IlyasDivision of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Markcus LeeDivision of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Usman YaqoobDivision of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Sheng CaoDivision of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Rebecca G WellsDivision of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Vijay H ShahDivision of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Moira B HilscherDivision of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address: hilscher.moira@mayo.edu.

Funding

UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Robert H. Vonderheide · 1985 to 2026
$222.3M
Phenotypic Diversity in COVID-19UL1TR001878 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2016 to 2025
$102.4M
PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI Samar Ibrahim · 2009 to 2026
$22.2M
Institutional Career Development CoreKL2TR002379 · NCATS · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2017 to 2026
$14.9M
Institutional Clinical and Translational Science AwardKL2TR001879 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI MEAGHER, EMMA ANNE · 2016 to 2025
$13.7M
Molecular Mechanisms of Portal HypertensionR01DK059615 · NIDDK · MAYO CLINIC ROCHESTER · PI SHAH, VIJAY H. · 2002 to 2023
$6.4M
Molecular Mechanisms of Liver Fibrosis (Diversity Supplement)R37AA021171 · NIAAA · MAYO CLINIC ROCHESTER · PI VIJAY H. SHAH · 2019 to 2026
$3.0M
Molecular Mechanisms of Liver FibrosisR01AA021171 · NIAAA · MAYO CLINIC ROCHESTER · PI SHAH, VIJAY H. · 2012 to 2018
$2.5M
NIDDK Multidisciplinary Predoctoral Training in Discovery and Translational ResearchT32DK124190 · NIDDK · MAYO CLINIC ROCHESTER · PI DANIEL D BILLADEAU, MARK A. MC NIVEN · 2020 to 2026
$1.3M
Regulation of portal hypertension through neutrophil-platelet interactions in liver sinusoidsK08DK127064 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI HILSCHER, MOIRA B · 2021 to 2025
$804k
Molecular Mechanisms of Portal HypertensionR56DK059615 · NIDDK · MAYO CLINIC ROCHESTER · PI SHAH, VIJAY H · 2007 to 2007
$378k
Aperio VERSA Digital Slide Scanner, eSlide Manager Database, and Advanced Image Analysis SoftwareS10OD023465 · OD · UNIVERSITY OF PENNSYLVANIA · PI DURHAM, AMY CLEVELAND · 2018 to 2018
$329k
NCATS NIH HHS KL2 TR001879NCATS NIH HHS KL2 TR002379NCATS NIH HHS UL1 TR001878NCI NIH HHS P30 CA016520NIAAA NIH HHS R01 AA021171NIAAA NIH HHS R37 AA021171NIDDK NIH HHS K08 DK127064NIDDK NIH HHS P30 DK084567NIDDK NIH HHS R01 DK059615NIDDK NIH HHS R56 DK059615NIDDK NIH HHS T32 DK124190NIH HHS S10 OD023465
6 · The paper itself

Abstract

BACKGROUND &

aimsCongestion alters the microenvironment of the liver sinusoid along the portal-central axis. We studied spatial changes in immune cells in the sinusoid that contribute to congestive fibrosis and portal hypertension (PHTN).

methodsTo visualize the distribution of immune cells in congestive hepatopathy (CH), we performed imaging mass cytometry (IMC) on liver tissue from patients with CH, Fontan-associated liver disease (FALD), and controls. We performed partial ligation of the inferior vena cava (pIVCL) to simulate CH in mice and isolated primary liver cells for single-cell RNA-sequencing (scRNA-seq) to study zonation of liver sinusoidal endothelial cells (LSECs). After pIVCL, mice were treated with intraperitoneal injections of AMG487, an inhibitor of the CXCL9 receptor, or a neutralizing antibody to CXCL9.

resultsIntra-hepatic macrophages are enriched in CH and FALD. Given the role of CXCL9 in macrophage patterning in the liver, we performed RNA in situ hybridization (RNAish) in CH and determined that CXCL9 was highly expressed in LSECs in FALD, suggesting that LSECs recruit macrophages in CH. After pIVCL, treatment with AMG487 or an antibody to CXCL9 attenuated portal pressures, fibrosis, and intra-hepatic macrophages. To study changes in LSECs that promote macrophage chemotaxis, we performed scRNA-seq after pIVCL and sham procedures. Analysis revealed 3 LSEC subpopulations according to sinusoidal location. RNAish identified peri-central LSECs as the predominant source of CXCL9 in FALD. In vitro analyses revealed that β-catenin and hypoxia inducible factor-1 α regulate CXCL9 transcription in peri-central LSECs.

conclusionsCXCL9 derived from peri-central LSECs enriches intra-hepatic macrophages in CH and FALD, contributing to congestive fibrosis and PHTN. Strategies to target LSEC-derived CXCL9 may prevent the progression of CH and FALD.

Indexed as

Chemokine CXCL9Endothelial CellsHypertension, PortalLiverMacrophagesAnimalsDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLChemokine CXCL9CXCL9 protein, humanCxcl9 protein, mouseFibrosisFontan-associated Liver DiseaseHypoxiaImaging Mass CytometryPortal Hypertension

Identifiers

PMID39923846
PMCPMC12198043

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.